Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5920610 | 1.00 | LMNA (0.32) | LMNAMAPK1HTTRAB9AKCNQ3 | |
| SCHEMBL5920620 | 1.00 | LMNA (0.32) | LMNAMAPK1HTTRAB9AKCNQ3 | |
| SCHEMBL6373105 | 0.79 | NR3C1 (0.33) | MAPK1 | |
| SCHEMBL6373108 | 0.79 | NR3C1 (0.33) | MAPK1 | |
| SCHEMBL6373102 | 0.79 | NR3C1 (0.33) | MAPK1 | |
| SCHEMBL6405030 | 0.78 | NR3C1 (0.45) | — | |
| SCHEMBL5780489 | 0.78 | NR3C1 (0.45) | — | |
| SCHEMBL6405037 | 0.78 | NR3C1 (0.45) | — | |
| SCHEMBL3550011 | 0.78 | — | — | |
| SCHEMBL3550006 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786823-B1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1786823-A1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2006-04-20 | — | — | US | disclosed |
| WO-2006027236-A1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | PTGES, PTGS1, PTGES2 | LMNA 3160/4885MAPK1 856/4885HTT 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.